Zhang Yiyao, Liu Li, Fan Pei, Bauer Nathalie, Gladkich Jury, Ryschich Eduard, Bazhin Alexandr V, Giese Nathalia A, Strobel Oliver, Hackert Thilo, Hinz Ulf, Gross Wolfgang, Fortunato Franco, Herr Ingrid
Molecular OncoSurgery, University of Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Section Surgical Research, University of Heidelberg, Heidelberg, Germany.
Oncotarget. 2015 Apr 30;6(12):9999-10015. doi: 10.18632/oncotarget.3171.
Pancreatic ductal adenocarcinoma (PDA) is characterized by an extremely poor prognosis. An inflammatory microenvironment triggers the pronounced desmoplasia, the selection of cancer stem-like cells (CSCs) and therapy resistance. The anti-inflammatory drug aspirin is suggested to lower the risk for PDA and to improve the treatment, although available results are conflicting and the effect of aspirin to CSC characteristics and desmoplasia in PDA has not yet been investigated. We characterized the influence of aspirin on CSC features, stromal reactions and gemcitabine resistance. Four established and 3 primary PDA cell lines, non-malignant cells, 3 patient tumor-derived CSC-enriched spheroidal cultures and tissues from patients who did or did not receive aspirin before surgery were analyzed using MTT assays, flow cytometry, colony and spheroid formation assays, Western blot analysis, antibody protein arrays, electrophoretic mobility shift assays (EMSAs), immunohistochemistry and in vivo xenotransplantation. Aspirin significantly induced apoptosis and reduced the viability, self-renewal potential, and expression of proteins involved in inflammation and stem cell signaling. Aspirin also reduced the growth and invasion of tumors in vivo, and it significantly prolonged the survival of mice with orthotopic pancreatic xenografts in combination with gemcitabine. This was associated with a decreased expression of markers for progression, inflammation and desmoplasia. These findings were confirmed in tissue samples obtained from patients who had or had not taken aspirin before surgery. Importantly, aspirin sensitized cells that were resistant to gemcitabine and thereby enhanced the therapeutic efficacy. Aspirin showed no obvious toxic effects on normal cells, chick embryos or mice. These results highlight aspirin as an effective, inexpensive and well-tolerated co-treatment to target inflammation, desmoplasia and CSC features PDA.
胰腺导管腺癌(PDA)的预后极差。炎症微环境会引发显著的促结缔组织增生、癌干细胞(CSC)的选择以及治疗抗性。尽管现有结果相互矛盾,且阿司匹林对PDA中CSC特征和促结缔组织增生的影响尚未得到研究,但抗炎药物阿司匹林被认为可降低PDA风险并改善治疗效果。我们对阿司匹林对CSC特征、基质反应和吉西他滨抗性的影响进行了表征。使用MTT分析、流式细胞术、集落和球体形成分析、蛋白质印迹分析、抗体蛋白阵列、电泳迁移率变动分析(EMSA)、免疫组织化学和体内异种移植,对4种已建立的和3种原发性PDA细胞系、非恶性细胞、3种患者肿瘤来源的富含CSC的球形培养物以及术前接受或未接受阿司匹林治疗的患者组织进行了分析。阿司匹林显著诱导细胞凋亡,并降低了细胞活力、自我更新潜能以及参与炎症和干细胞信号传导的蛋白质表达。阿司匹林还降低了体内肿瘤的生长和侵袭,并与吉西他滨联合使用时显著延长了原位胰腺异种移植小鼠的生存期。这与进展、炎症和促结缔组织增生标志物的表达降低有关。这些发现在用术前服用或未服用阿司匹林的患者获得的组织样本中得到了证实。重要的是,阿司匹林使对吉西他滨耐药的细胞敏感,从而提高了治疗效果。阿司匹林对正常细胞、鸡胚或小鼠没有明显的毒性作用。这些结果突出了阿司匹林作为一种有效、廉价且耐受性良好的联合治疗药物,可针对PDA的炎症、促结缔组织增生和CSC特征。